Literature DB >> 18200001

T-type calcium channel blockade as a therapeutic strategy against renal injury in rats with subtotal nephrectomy.

N Sugano1, S Wakino, T Kanda, S Tatematsu, K Homma, K Yoshioka, K Hasegawa, Y Hara, Y Suetsugu, T Yoshizawa, Y Hara, Y Utsunomiya, G Tokudome, T Hosoya, T Saruta, K Hayashi.   

Abstract

T-type calcium channel blockers have been previously shown to protect glomeruli from hypertension by regulating renal arteriolar tone. To examine whether blockade of these channels has a role in protection against tubulointerstitial damage, we used a stereo-selective T-type calcium channel blocker R(-)-efonidipine and studied its effect on the progression of this type of renal injury in spontaneously hypertensive rats that had undergone subtotal nephrectomy. Treatment with racemic efonidipine for 7 weeks significantly reduced systolic blood pressure and proteinuria. The R(-)-enantiomer, however, had no effect on blood pressure but significantly reduced proteinuria compared to vehicle-treated rats. Both agents blunted the increase in tubulointerstitial fibrosis, renal expression of alpha-smooth muscle actin and vimentin along with transforming growth factor-beta (TGF-beta)-induced renal Rho-kinase activity seen in the control group. Subtotal nephrectomy enhanced renal T-type calcium channel alpha1G subunit expression mimicked in angiotensin II-stimulated mesangial cells or TGF-beta-stimulated proximal tubular cells. Our study shows that T-type calcium channel blockade has renal protective actions that depend not only on hemodynamic effects but also pertain to Rho-kinase activity, tubulointerstitial fibrosis, and epithelial-mesenchymal transitions.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18200001     DOI: 10.1038/sj.ki.5002793

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  13 in total

Review 1.  Development of newer calcium channel antagonists: therapeutic potential of efonidipine in preventing electrical remodelling during atrial fibrillation.

Authors:  Narutaka Ohashi; Hideo Mitamura; Satoshi Ogawa
Journal:  Drugs       Date:  2009       Impact factor: 9.546

2.  Ca(2+) channel blocker benidipine promotes coronary angiogenesis and reduces both left-ventricular diastolic stiffness and mortality in hypertensive rats.

Authors:  Takao Nishizawa; Xian Wu Cheng; Zhehu Jin; Koji Obata; Kohzo Nagata; Akihiro Hirashiki; Takeshi Sasaki; Akiko Noda; Kyosuke Takeshita; Hideo Izawa; Guo-Ping Shi; Masafumi Kuzuya; Kenji Okumura; Toyoaki Murohara
Journal:  J Hypertens       Date:  2010-07       Impact factor: 4.844

3.  T-type calcium channel blocker attenuates unilateral ureteral obstruction-induced renal interstitial fibrosis by activating the Nrf2 antioxidant pathway.

Authors:  Sungjin Chung; Soojeong Kim; Minyoung Kim; Eun Sil Koh; Hye Eun Yoon; Ho-Shik Kim; Cheol Whee Park; Yoon Sik Chang; Seok Joon Shin
Journal:  Am J Transl Res       Date:  2016-11-15       Impact factor: 4.060

4.  Anti-proliferative actions of T-type calcium channel inhibition in Thy1 nephritis.

Authors:  Andrea Cove-Smith; Christopher J Mulgrew; Olena Rudyk; Neelanjana Dutt; Linda M McLatchie; Michael J Shattock; Bruce M Hendry
Journal:  Am J Pathol       Date:  2013-06-05       Impact factor: 4.307

Review 5.  Dissecting fibrosis: therapeutic insights from the small-molecule toolbox.

Authors:  Carmel B Nanthakumar; Richard J D Hatley; Seble Lemma; Jack Gauldie; Richard P Marshall; Simon J F Macdonald
Journal:  Nat Rev Drug Discov       Date:  2015-09-04       Impact factor: 84.694

6.  miR-34c-5p and CaMKII are involved in aldosterone-induced fibrosis in kidney collecting duct cells.

Authors:  Eui-Jung Park; Hyun Jun Jung; Hyo-Jung Choi; Jeong-In Cho; Hye-Jeong Park; Tae-Hwan Kwon
Journal:  Am J Physiol Renal Physiol       Date:  2017-10-25

7.  Role of mineralocorticoid receptor/Rho/Rho-kinase pathway in obesity-related renal injury.

Authors:  H Tokuyama; S Wakino; Y Hara; N Washida; K Fujimura; K Hosoya; K Yoshioka; K Hasegawa; H Minakuchi; K Homma; K Hayashi; H Itoh
Journal:  Int J Obes (Lond)       Date:  2011-12-20       Impact factor: 5.095

8.  Effect of Angiotensin-Converting Enzyme Inhibitor/Calcium Antagonist Combination Therapy on Renal Function in Hypertensive Patients With Chronic Kidney Disease: Chikushi Anti-Hypertension Trial - Benidipine and Perindopril.

Authors:  Tetsu Okuda; Keisuke Okamura; Kazuyuki Shirai; Hidenori Urata
Journal:  J Clin Med Res       Date:  2017-12-30

9.  Oral adsorbent AST-120 ameliorates gut environment and protects against the progression of renal impairment in CKD rats.

Authors:  Ayumi Yoshifuji; Shu Wakino; Junichiro Irie; Ayumi Matsui; Kazuhiro Hasegawa; Hirobumi Tokuyama; Koichi Hayashi; Hiroshi Itoh
Journal:  Clin Exp Nephrol       Date:  2018-04-19       Impact factor: 2.801

10.  Benidipine protects kidney through inhibiting ROCK1 activity and reducing the epithelium-mesenchymal transdifferentiation in type 1 diabetic rats.

Authors:  Ganlin Wu; Meirong Xu; Kui Xu; Yilan Hu
Journal:  J Diabetes Res       Date:  2013-12-01       Impact factor: 4.011

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.